Page 108 - Biomarkers for risk stratification and guidance in heart failure

Table 1. continued
NT-proBNP at
admission, pg/mL
Discharge
NYHA functional class ≥III
Mean arterial pressure, mm Hg Heart rate, beats/ min
QRS duration, ms
LVEF, % Hemoglobin, mmol/L
Sodium, mmol/L Potassium, mmol/L Urea, mmol/L Creatinine, μmol/L eGFR, mL/min NT-proBNP, pg/mL NT-proBNP decrease
during index
hospitalization, %
7,897 (4,345-14,030)
67 (21.7)
85.5 (12.9)
76.8 (15.6)
112 (94-140)
35.9 (14.3) 8.5 (1.2)
139.2 (3.5) 4.3 (0.5)
11.7 (8.4-15.9)
119 (100-158) 48.1 (33.2-63.9) 2,936 (1,344-5,505) 61.8 (43.2-76.6)
7,561 (4,120-12,340)
9 (14.5)
88.5 (11.5)
77.3 (18.2)
102 (89-125) 37.7 (14.0) 8.8 (1.4)
139.8 (3.7)
4.2 (0.4)
9.9 (7.4-12.7) 103 (88-124) 60.1 (45.6-69.5) 1,531 (854-2,544) 79.4 (69.6-83.9)
60 (96.8) 51 (82.3) 6 (9.7) 46 (74.2) 33 (53.2)
14 (22.6)
89.3 (12.1)
8.6 (6.6-11.0)
102 (87-140) -42.0 (-20.8 to -63.9)
663 (387-1,360)
5,101 (3,234-10,491)
25 (26.6)
88.4 (13.5)
77.4 (15.7)
103 (92-128) 36.7 (14.3) 8.8 (1.1)
139.6 (3.5)
4.3 (0.5)
10.7 (8.2-14.6) 114 (98-149) 50.4 (39.3-65.0) 1,608 (892-3,847) 66.8 (51.5-79.0)
90 (95.7) 68 (72.3) 18 (19.1) 76 (80.9) 44 (46.8)
33 (35.1)
86.4 (13.0)
10.3 (7.2-13.8) 119 (101-148) -7.2 (-44.2 to 42.6)
1,598 (1,051-2,159)
12,280 (6,542-17,597)
17 (20.5)
82.6 (11.0)
76.0 (14.8)
116 (100-138)
33.6 (13.7) 8.3 (1.2)
138.7 (3.0)
4.3 (0.4)
12.6 (8.2-17.2) 131 (105-168) 42.9 (31.1-59.5) 4,398(2,512-6,712) 57.4(37.6-71.7)
81 (97.6) 56 (67.5) 20 (24.1) 64 (77.1) 46 (55.4)
23 (27.7)
82.0 (14.7)
12.5 (8.8-18.0) 133 (105-180) 8.0 (-15.8 to 54.3)
4,661 (3,052-6,958)
8,618 <.001 (4,915-15,729)
16 (22.9) .342
82.3 (14.2) .001
76.6 (14.3) .938
131 (98-170) .002
35.8 (15.4) .381 8.0 (1.1) .003
138.9 (4.0) .154
4.3 (0.5) .685
14.3 (10.6-19.0) <.001 5 149 (111-209) <.001
39.6 (24.7-54.6) <.001
5,112(2,873-8,429) <.001
41.5 (29.7-51.2) <.001
68 (97.1) .945 47 (67.1) .182 16 (22.9) .140 51 (72.9) .631 41 (58.6) .477
17 (24.3) .289
81.4 (13.1) .001
14.9 (10.7-22.7) <.001 160 (127-205) <.001 45.2 (25.1-89.9) <.001
7,614 <.001 (4,949-12,928)
Diuretics
ACE inhibitors ARB Beta-blockers Aldosterone antagonists Digoxin
299 (96.8) 222 (71.8) 60 (19.4) 237 (76.7) 164 (53.1)
87 (28.2)
Outpatient visit at 1 month
Mean arterial pressure, mm Hg Urea, mmol/L Creatinine, μmol/L Early outpatient change NT-proBNP, % NT-proBNP, pg/mL
84.7 (13.6)
11.0 (8.3-16.7) 130 (100-167)
3.5(-34.2 to 46.3)
2,538 (1,272-5,434)
Serial NT-proBNP measurements during and early after HF admission.
Medication at discharge
NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ICD, implantable cardiac defibrillator; HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; ACE,
107
Patient Characteristic
Overall (n = 309)
Group 1: 0 Points (n = 62)
Group 2: 1 Point (n = 94)
Group 3: 2 Points (n = 83)
Group 4: 3 Points (n = 70)
P Value (Overall)